Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Whitehead Institute for Biomedical Research
Headquarters: Cambridge, MA, United States of America
Website: http://wi.mit.edu/
Year Founded: 1982
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 21, 2025
Editor's Commentary
Solving CNS delivery will open big doors for epigenome editing: a Perspective
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
BioCentury | Jul 3, 2024
Discovery & Translation
Science Spotlight: Epigenetic editor for brain prion silencing, Mopac’s oral biologics and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 12, 2023
Discovery & Translation
Lurie winners show mitochondria is more than a powerhouse
Northwestern’s Navdeep Chandel and Harvard’s Vamsi Mootha share the FNIH’s 2023 prize for pioneering mitochondrial biology beyond ATP
BioCentury | Jan 21, 2023
Discovery & Translation
Epigenome editing for X-linked diseases; plus a rapid platform for human mAb generation and more
BioCentury’s roundup of translational news
BioCentury | Jun 24, 2022
Emerging Company Profile
DEM BioPharma: exploring ‘don’t eat me’ white space beyond CD47
Backed with $70M, the start-up unites Trillium alumni with academics to discover more phagocytosis targets for cancer
BioCentury | Apr 6, 2022
Management Tracks
Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
BioCentury | Aug 24, 2021
Deals
Aug. 23 Quick Takes: Pfizer, BioNTech look ahead to pediatric data after FDA approval of Comirnaty
Approval for COVID-19 vaccines from Zydus Cadila, Medigen-Dynavax; plus Sabatini fired, Clover’s U.S. beachhead and more
BioCentury | Aug 6, 2021
Management Tracks
New CMO, CSO at Black Diamond
Plus updates from Adaptive, Homology and more
BioCentury | Sep 29, 2020
Finance
With $77M series B, condensates company Dewpoint aiming for proof of concept
Dewpoint’s $77 million series B round affords the company “breathing room to make good decisions” as it chooses programs to develop and partner based on the science of
BioCentury | Jul 3, 2020
Management Tracks
Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more
Items per page:
1 - 10 of 150